(SWL) Versus (ODT) Versus Combined SWL And ODT For Radiolucent Stone

Not Applicable

Completed

• Conditions: ESWL; Dissolution; Stone, Urinary; Radiolucent Calculus of Urinary Tract; Urologic Diseases; Stone, Kidney
• Interventions: Procedure: Dissolution therapy; Procedure: Ultrasound guided SWL; Procedure: Combined ultrasound guided SWL and dissolution therapy

• Registration Number: NCT03388060
• Lead Sponsor: Mansoura University

Brief Summary

compare the efficacy of of ultrasound guided SWL versus dissolution therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm renal stones.

Detailed Description

Urolithiasis is a common morbidity worldwide, affecting 10% to 15% of the population in Europe and North America. A higher prevalence of stone disease is found in hot or dry areas, including 20% to 25% in the Middle East. Radiolucent stones are mostly uric acid (UA) calculi, which varies geographically with worldwide incidence ranges from 5 to 40% and about 7- 10 percent of all calculi. Other rare radiolucent stones include xanthine and 2,8-dihydroxyadenine calculi.

The main etiologic factors for the development of uric acid nephrolithiasis are low urinary pH, hyperuricosuria, and low urinary volume. Practically, all of those who form uric acid stones have persistently low urinary pH, and most excrete normal amounts of uric acid. This suggests the potential importance of urinary pH manipulation in dissolving UA stones. Dissolution therapy for UA calculi is based on hydration and raising the urinary pH. European guidelines recommended that urine pH should be increased to a level above 6. The early published papers discussed the efficacy of oral chemo-dissolution therapy reporting high success rates. Since that era, there have been only a few publications, with widely variable results (15-80% complete dissolution rate).

Retrograde intrarenal surgery (RIRS), shockwave lithotripsy (SWL), and percutaneous nephrolithotomy (PCNL) are the three main non-medical modalities for treating medium-sized renal stones. Resorlu et al., retrospectively compare the outcomes of SWL, PNL, and RSIS for 10-20 mm radiolucent renal calculi of 437 patients and concluded that success rates "defined as stone-free status or asymptomatic insignificant residual fragments \<3 mm." were 66.5, 91.4, and 87 % for SWL, PNL, and RIRS (p\<0.001). in a prospective randomized of 135 patient with 1 to 2 cm radiolucent lower calyceal renal calculi, the 3-month stone-free rate of SWL, RIRS and miniperc was 73.8%, 86.1% and 95.1%, respectively (p =0.01).

Comparing the medical in the form of dissolution therapy versus non-medical in the form of SWL, Elderwy et al, in a prospective study on 87 children with radiolucent renal calculi with length less than 25 mm and a normal upper urinary tract or grade I HN, found that stone-free rate was 72.9% for dissolution therapy vs 82.1% after a single session of shock wave lithotripsy (p = 0.314).

Dissolution success is related to stone size as well as compliance. Larger stones demand longer therapy, and in these cases SWL may increase treatment efficacy by increasing stone surface area. So when Mokhless et al., use combined extracorporeal shock wave lithotripsy and dissolution therapy in radiolucent stone 12-65 mm in the largest diameter, stone-free rate of 100% was achieved in all 24 children after 3 months.9 To the best of our knowledge, there is no controlled trial comparing the efficacy of ultrasound guided SWL versus dissolution therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm single renal stone.

Study Timeline

• Study Start: 2017-04-01
• Study First Submitted: 2017-12-23
• Study First Submitted QC: 2017-12-23
• Study First Posted: 2018-01-02
• Primary Completion: 2018-03-30
• Study Completion: 2018-03-30
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-02
• Last Update Posted: 2018-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Adult patient with 1-2.5 cm renal stones.
• Normal Serum creatinine
• Radiolucent stone by X-ray

Exclusion Criteria

• Pregnancy.
• Bleeding diatheses.
• Patients with a pacemaker.
• Uncontrolled UTIs.
• Severe skeletal malformations.
• Severe obesity which prevent targeting of the stone; BMI (40 or more).
• Arterial aneurysm in the vicinity of the stone.
• Anatomical obstruction distal to the stone.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dissolution therapy	Dissolution therapy	Dissolution therapy for Radiolucent stone
Ultrasound guided SWL	Ultrasound guided SWL	ultrasound guided SWL for Radiolucent stone
Combined ultrasound guided SWL and dissolution therapy	Combined ultrasound guided SWL and dissolution therapy	Combined treatment for Radiolucent stone.

Primary Outcome Measures

Name	Time	Method
Stone free rate	3 months	Free renal units from stones

Trial Locations

Locations (1)

Urology and Nephrology Center; 🇪🇬 Mansourah, Aldakahlia, Egypt